Neurocrine Biosciences | NBIX - Le Coût Des Ventes





Le Coût Des Ventes Changement Date
AbbVie USD 4.22B 329M 2026-03
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 73.25M 27.04M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Cytokinetics USD 160K 104.24M 2026-03
Exelixis USD 19.95M 6.53M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Prothena USD 28.94M 11.58M 2025-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Repligen USD 85.97M 8.11M 2026-03
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Teva Pharmaceutical Industries USD 2.01B 46M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03
Xoma 116K 112.7K 2024-06